Former Vice Premier Tsai Ing-wen (蔡英文) and AIDS research pioneer David Ho (何大一) will lead a new biotech company that will be jointly owned by the government and private investors to speed up the research and development of AIDS drugs, the nation's top economic planner said yesterday.
Ho Mei-yueh (何美玥), chairwoman of the Council for Economic Planning and Development, said the state-owned National Development Fund (NDF) would help finance the establishment of TaiMed Biologics Co (宇昌生技), which is planning to raise US$50 million in capital. Mo said the NDF plans to hold a 40 percent share in the company.
The government has authorized Tsai to assume the chairmanship and David Ho, a Taiwan-born AIDS expert and director of the New York-based Aaron Diamond AIDS Research Center, would serve as a co-founder of TaiMed Biologics, which would be a subsidiary of TaiMed Inc (台懋公司), a Taiwan-based biotech firm, Ho said.
Noting that TaiMed Biologics has gained patent authorization from US-based Genentech Inc for its lead clinical product, TNX-355, a potential treatment for HIV and AIDS patients, Ho said it marks a breakthrough in Taiwan's biotech industry.
She said the US company reported positive results in a Phase 2 clinical trial of TNX-355 and that a Phase 2b trial is expected to be conducted in the fourth quarter of this year in the US, Europe and South America.
TaiMed Biologics will be located in the Hsinchu Biomedical Park (新竹生醫園區) and will be the first enterprise to be set up in the park.
Other members of the TaiMed Biologics board of directors include Academia Sinica President Wong Chi-huey (翁啟惠), Lee Yuan-tseh (李遠哲), a Nobel laureate and former president of the Academic Sinica and Chen Lan-bo (陳良博), founder of Synta Pharmaceuticals Corp, a biopharmaceutical company.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) secured a record 70.2 percent share of the global foundry business in the second quarter, up from 67.6 percent the previous quarter, and continued widening its lead over second-placed Samsung Electronics Co, TrendForce Corp (集邦科技) said on Monday. TSMC posted US$30.24 billion in sales in the April-to-June period, up 18.5 percent from the previous quarter, driven by major smartphone customers entering their ramp-up cycle and robust demand for artificial intelligence chips, laptops and PCs, which boosted wafer shipments and average selling prices, TrendForce said in a report. Samsung’s sales also grew in the second quarter, up
LIMITED IMPACT: Investor confidence was likely sustained by its relatively small exposure to the Chinese market, as only less advanced chips are made in Nanjing Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) saw its stock price close steady yesterday in a sign that the loss of the validated end user (VEU) status for its Nanjing, China, fab should have a mild impact on the world’s biggest contract chipmaker financially and technologically. Media reports about the waiver loss sent TSMC down 1.29 percent during the early trading session yesterday, but the stock soon regained strength and ended at NT$1,160, unchanged from Tuesday. Investors’ confidence in TSMC was likely built on its relatively small exposure to the Chinese market, as Chinese customers contributed about 9 percent to TSMC’s revenue last
Taiwan and Japan will kick off a series of cross border listings of exchange-traded funds (ETFs) this month, a milestone for the internationalization of the local ETF market, the Taiwan Stock Exchange (TWSE) said Wednesday. In a statement, the TWSE said the cross border ETF listings between Taiwan and Japan are expected to boost the local capital market’s visibility internationally and serve as a key for Taiwan becoming an asset management hub in the region. An ETF, a pooled investment security that is traded like an individual stock, can be tracked from the price of a single stock to a large and
Despite global geopolitical uncertainties and macroeconomic volatility, DBS Bank Taiwan (星展台灣) yesterday reported that its first-half revenue rose 10 percent year-on-year to a record NT$16.5 billion (US$537.8 million), while net profit surged 65 percent to an unprecedented NT$4.4 billion. The nation’s largest foreign bank made the announcement on the second anniversary of its integration with Citibank Taiwan Ltd’s (花旗台灣) consumer banking business. “Taiwan is a key market for DBS. Over the years, we have consistently demonstrated our commitment to deepening our presence in Taiwan, not only via continued investment to support franchise growth, but also through a series of bolt-on acquisitions,” DBS
RSS